Abstract
Once-daily osmotic controlled-release (OROS) methylphenidate (Concerta) in the treatment of 407 children, aged 6-13 years, with ADHD who were known MPH responders, was evaluated in a 24-month multicenter, open-label, nonrandomized study, and reported from the Massachusetts General Hospital, Boston.
Highlights
Hereditary rippling muscle disease (RMD) is a rare autosomal dominant, nonprogressive myopathy characterized by increased muscle irritability, electrically silent wave-like contractions, and muscle mounding with percussion
The long-term sequelae and early predictors of sequelae were determined in a chart review of 47 children with Guillain-Barre syndrome (GBS) of whom 30 had been treated with intravenous gammaglobulin (IVIG) at The Hospital for Sick Children, Toronto, Canada
Persisting long-term muscle weakness at least 2 years after recovery was present in 23% of cases
Summary
The long-term sequelae and early predictors of sequelae were determined in a chart review of 47 children with Guillain-Barre syndrome (GBS) of whom 30 had been treated with intravenous gammaglobulin (IVIG) at The Hospital for Sick Children, Toronto, Canada. Hereditary rippling muscle disease (RMD) is a rare autosomal dominant, nonprogressive myopathy characterized by increased muscle irritability (percussion-induced contractions), electrically silent wave-like contractions (rippling muscle), and muscle mounding with percussion. The above authors have previously reported mutations in CAV-3 in families with RMD and in one sporadic case of RMD. CAV-3 mutations may occur in limb-girdle muscular dystrophy 1C, distal myopathy, and in children with elevated CK without myopathy.
Sign-in/Register to view highlights & summary Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
